CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer.

At CG Oncology, we see a world where urologic cancer patients can benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life.

Our product candidate, cretostimogene grenadenorepvec, is an investigational engineered oncolytic immunotherapy. In BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), cretostimogene has shown clinical benefit and has been generally well-tolerated as both a monotherapy and in combination with other therapies in clinical trials.

Click here to view our Executive Leadership.

Click here to view our Board of Directors.

Unmet Need in Bladder Cancer

people will be diagnosed with Bladder Cancer this year1

most common type of cancer in the US

Non-muscle invasive bladder
cancer (NMIBC) represents

%

of newly diagnosed bladder cancer cases2

Only

%

of High-Grade patients with T1 disease, where cystectomy is guideline recommended after BCG fails, will undergo a cystectomy3-6

%

of high-risk patients will recur within 1 year7

Up to

%

of patients either do not respond or eventually develop disease recurrence after first-line BCG therapy7

REFERENCES:

1. Cancer of the Urinary Bladder – Cancer Stat Facts. SEER. https://seer.cancer.gov/statfacts/html/urinb.html. Accessed January, 2024.

2. Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, Pruthi R, Quale DZ, Ritch CR, Seigne JD, Skinner EC, Smith ND, McKiernan JM (2016). Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol. 196:1021-1029.

3. Berger I, Xia L, Wirtalla C, Dowzicky P, Guzzo TJ, Kelz RR. 30-day readmission after radical cystectomy: Identifying targets for improvement using the phases of surgical care. Can Urol Assoc J. 2018;13(7):E190-e201.

4. Sadowski DJ, Warner H, Scaife S, McVary KT, Alanee SR. 30-day all-cause hospital readmission after cystectomy: No worse for rural Medicare residents. Urol Oncol. 2018;36(3):89.e87-89.e11.

5. Pak JS, Lee JJ, Bilal K, Finkelstein M, Palese MA. Utilization trends and short-term outcomes of robotic versus open radical cystectomy for bladder cancer. Urology. 2017;103:117-123.

6. Maiboma SL, Poulsena AM, Thind PO, Sallinga ML, Sallinga LN, Kehletb H, Brassoa K, Joensena UN, (2021). Morbidity and Days Alive and Out of Hospital Within 90 Days Following Radical Cystectomy for Bladder Cancer. European Journal of Urology 28(28) 1-8.www.sciencedirect.com

7.  Richard J Sylvester 1, Adrian P M van der Meijden, Willem Oosterlinck, J Alfred Witjes, Christian Bouffioux, Louis Denis, Donald W W Newling, Karlheinz Kurth. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Uro.  2006 Mar;49(3):466-5; discussion 475-7.  doi: 10.1016/j.eururo.2005.12.031. Epub 2006 Jan 17.